Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 438.06
ACHN's Cash to Debt is ranked higher than
54% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: 68.31 vs. ACHN: 438.06 )
Ranked among companies with meaningful Cash to Debt only.
ACHN' s 10-Year Cash to Debt Range
Min: 1.1  Med: 98.72 Max: No Debt
Current: 438.06
Equity to Asset 0.91
ACHN's Equity to Asset is ranked higher than
85% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ACHN: 0.91 )
Ranked among companies with meaningful Equity to Asset only.
ACHN' s 10-Year Equity to Asset Range
Min: -6.98  Med: 0.64 Max: 0.91
Current: 0.91
-6.98
0.91
F-Score: 2
Z-Score: 23.96
M-Score: 3.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -12097.33
ACHN's Operating margin (%) is ranked lower than
94% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -71.95 vs. ACHN: -12097.33 )
Ranked among companies with meaningful Operating margin (%) only.
ACHN' s 10-Year Operating margin (%) Range
Min: -17954.25  Med: -756.76 Max: 11879.49
Current: -12097.33
-17954.25
11879.49
Net-margin (%) -12025.88
ACHN's Net-margin (%) is ranked lower than
94% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -68.66 vs. ACHN: -12025.88 )
Ranked among companies with meaningful Net-margin (%) only.
ACHN' s 10-Year Net-margin (%) Range
Min: -17897.17  Med: -731.65 Max: 12030.34
Current: -12025.88
-17897.17
12030.34
ROE (%) -47.66
ACHN's ROE (%) is ranked lower than
61% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. ACHN: -47.66 )
Ranked among companies with meaningful ROE (%) only.
ACHN' s 10-Year ROE (%) Range
Min: -199.15  Med: -77.16 Max: -46.56
Current: -47.66
-199.15
-46.56
ROA (%) -44.16
ACHN's ROA (%) is ranked lower than
65% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: -26.75 vs. ACHN: -44.16 )
Ranked among companies with meaningful ROA (%) only.
ACHN' s 10-Year ROA (%) Range
Min: -181.02  Med: -62.76 Max: -43.23
Current: -44.16
-181.02
-43.23
ROC (Joel Greenblatt) (%) -5226.61
ACHN's ROC (Joel Greenblatt) (%) is ranked lower than
79% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: -365.20 vs. ACHN: -5226.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ACHN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6041.18  Med: -1930.46 Max: -457.53
Current: -5226.61
-6041.18
-457.53
EBITDA Growth (3Y)(%) 1.00
ACHN's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: -4.40 vs. ACHN: 1.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ACHN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -31.90 Max: 4.1
Current: 1
0
4.1
EPS Growth (3Y)(%) 0.50
ACHN's EPS Growth (3Y)(%) is ranked higher than
58% of the 420 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. ACHN: 0.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ACHN' s 10-Year EPS Growth (3Y)(%) Range
Min: -65.5  Med: -22.50 Max: 3.4
Current: 0.5
-65.5
3.4
» ACHN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ACHN Guru Trades in Q3 2014

Jim Simons 897,300 sh (New)
Steven Cohen 1,048,100 sh (+91.54%)
Paul Tudor Jones 45,217 sh (+70.04%)
Chuck Royce 2,262 sh (unchged)
» More
Q4 2014

ACHN Guru Trades in Q4 2014

John Burbank 36,104 sh (New)
John Burbank 207,000 sh (unchged)
Jim Simons Sold Out
Chuck Royce Sold Out
Steven Cohen 621,900 sh (-40.66%)
Paul Tudor Jones 13,942 sh (-69.17%)
» More
Q1 2015

ACHN Guru Trades in Q1 2015

Steven Cohen Sold Out
Paul Tudor Jones Sold Out
John Burbank Sold Out
» More
Q2 2015

ACHN Guru Trades in Q2 2015

Steven Cohen 8,388,200 sh (New)
Paul Tudor Jones 10,400 sh (New)
Steven Cohen 5,879,244 sh (+845.37%)
» More
» Details

Insider Trades

Latest Guru Trades with ACHN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.77
ACHN's P/B is ranked higher than
52% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. ACHN: 3.77 )
Ranked among companies with meaningful P/B only.
ACHN' s 10-Year P/B Range
Min: 0.79  Med: 4.01 Max: 17.77
Current: 3.77
0.79
17.77
P/S 1169.64
ACHN's P/S is ranked lower than
98% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.19 vs. ACHN: 1169.64 )
Ranked among companies with meaningful P/S only.
ACHN' s 10-Year P/S Range
Min: 0.78  Med: 142.84 Max: 1169.63
Current: 1169.64
0.78
1169.63
Current Ratio 10.48
ACHN's Current Ratio is ranked higher than
77% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. ACHN: 10.48 )
Ranked among companies with meaningful Current Ratio only.
ACHN' s 10-Year Current Ratio Range
Min: 1.06  Med: 6.16 Max: 19.64
Current: 10.48
1.06
19.64
Quick Ratio 10.48
ACHN's Quick Ratio is ranked higher than
77% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.01 vs. ACHN: 10.48 )
Ranked among companies with meaningful Quick Ratio only.
ACHN' s 10-Year Quick Ratio Range
Min: 1.06  Med: 6.16 Max: 19.64
Current: 10.48
1.06
19.64
Days Sales Outstanding 380.40
ACHN's Days Sales Outstanding is ranked lower than
95% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. ACHN: 380.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACHN' s 10-Year Days Sales Outstanding Range
Min: 12.29  Med: 88.26 Max: 163.73
Current: 380.4
12.29
163.73

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.13
ACHN's Price/Net Cash is ranked higher than
69% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 7.71 vs. ACHN: 4.13 )
Ranked among companies with meaningful Price/Net Cash only.
ACHN' s 10-Year Price/Net Cash Range
Min: 0.82  Med: 5.81 Max: 12.7
Current: 4.13
0.82
12.7
Price/Net Current Asset Value 4.06
ACHN's Price/Net Current Asset Value is ranked higher than
68% of the 537 Companies
in the Global Biotechnology industry.

( Industry Median: 6.85 vs. ACHN: 4.06 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ACHN' s 10-Year Price/Net Current Asset Value Range
Min: 0.78  Med: 5.33 Max: 12.29
Current: 4.06
0.78
12.29
Price/Tangible Book 3.79
ACHN's Price/Tangible Book is ranked higher than
60% of the 693 Companies
in the Global Biotechnology industry.

( Industry Median: 5.31 vs. ACHN: 3.79 )
Ranked among companies with meaningful Price/Tangible Book only.
ACHN' s 10-Year Price/Tangible Book Range
Min: 0.72  Med: 4.36 Max: 77.75
Current: 3.79
0.72
77.75
Price/Median PS Value 5.43
ACHN's Price/Median PS Value is ranked lower than
93% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: 1.08 vs. ACHN: 5.43 )
Ranked among companies with meaningful Price/Median PS Value only.
ACHN' s 10-Year Price/Median PS Value Range
Min: 0.01  Med: 1.03 Max: 6.24
Current: 5.43
0.01
6.24
Earnings Yield (Greenblatt) (%) -10.47
ACHN's Earnings Yield (Greenblatt) (%) is ranked lower than
61% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. ACHN: -10.47 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ACHN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -11.76  Med: 513.90 Max: 2697.4
Current: -10.47
-11.76
2697.4

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 22 38 75
EPS($) -0.23 -0.08 0.17
EPS without NRI($) -0.23 -0.08 0.17

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ADA.Germany,
Achillion Pharmaceuticals Inc was incorporated on August 17, 1998 in Delaware. The Company is a biopharmaceutical company which focuses on the discoveries, develops and commercializes treatments for infectious diseases. Within the anti-infective market, it is currently focusing its efforts on developing commercially competitive, short-duration combination therapies for the treatment of chronic hepatitis C infection that are administered once-daily, orally, and without ribavirin. The Company competes with Abbvie, Astra-Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Enanta, Gilead, GlaxoSmithKline, Idenix, Johnson & Johnson, Presidio, Medivir, Merck, Novartis, Pfizer, Roche, Valeant and Vertex. The Company's drug candidates is subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, record keeping, labeling, marketing and distribution of drugs.
» More Articles for ACHN

Headlines

Articles On GuruFocus.com
UBS and JMP Securities Downgrade Achillion Pharmaceuticals Inc.(ACHN) Following Johnson & Johnson (J May 21 2015 
Dycom Industries (DY) Surpasses Estimates; Achillion Pharma (ACHN) Inks Mega-Deal with Janssen May 20 2015 
Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 
Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels & Resort Aug 25 2014 
Top 4 Insider Buys of Last Week Jun 10 2013 
comment on ACHN Mar 15 2013 
comment on ACHN Mar 09 2013 
Achillion Will Surge If New Drug Is Successful Apr 21 2012 

More From Other Websites
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Aug 24 2015
ACHILLION PHARMACEUTICALS INC Financials Aug 20 2015
Achillion Pharmaceuticals (ACHN) Jumps: Stock Gains 16.7% Aug 18 2015
Peter Kolchinsky’s New Top Healthcare Pick And Old Favorites Aug 15 2015
Is It Time For Gilead Sciences To Buy Achillion? Aug 14 2015
10-Q for Achillion Pharmaceuticals, Inc. Aug 12 2015
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 10 2015
Achillion reports 2Q loss Aug 10 2015
Achillion reports 2Q loss Aug 10 2015
Achillion Reports Second Quarter and Six Month 2015 Financial Results Aug 10 2015
Achillion Announces That Janssen Has Initiated a Phase I Study to Evaluate the Effect of Simeprevir... Aug 03 2015
What Will Gilead Buy Next? 4 Possible Targets Jul 15 2015
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jul 01 2015
Achillion to Present at the JMP Securities Life Sciences Conference 2015 Jun 18 2015
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Jun 08 2015
Billionaire Steve Cohen Bullish Again (And Now More Than Ever) On Achillion Pharmaceuticals, Inc.... May 31 2015
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... May 27 2015
The Zacks Analyst Blog Highlights: Eleven Biotherapeutics, bluebird, Agios, Acceleron and Achillion... May 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK